Constitutive NFATc4‑HDAC3 Repression Safeguards Atrophy Genes; Age‑Related Calcineurin Decline Unmasks a Feed‑Forward Loop

Hypothesis

Constitutively nuclear NFATc4 functions as a basal transcriptional repressor of atrophy‑related E3 ligases (atrogin‑1/MAFbx and MuRF1) by recruiting the HDAC3‑containing co‑repressor complex to their enhancers. In young, active muscle, calcineurin activity sustains NFATc4 in a dephosphorylated state that promotes its interaction with HDAC3, keeping atrophy genes silent. With advancing age or denervation‑induced inactivity, calcineurin activity drops (as shown by rapid NFATc1 export after just 2 h of inactivity) [2], leading to a shift toward phosphorylated NFATc4 that has reduced affinity for HDAC3. Loss of this repression permits basal transcription of atrogin‑1 and MuRF1, initiating ubiquitin‑proteasome‑mediated degradation of contractile proteins. Importantly, the newly synthesized atrogin‑1 then ubiquitinates calcineurin subunits for proteasomal destruction [3], creating a feed‑forward loop that further diminishes calcineurin/NFAT signaling and accelerates sarcopenia. This model predicts that (i) HDAC3 occupancy at the atrogin‑1 and MuRF1 enhancers will be high in young soleus and diminish with age or denervation, (ii) pharmacological inhibition of HDAC3 will phenocopy the aged state by derepressing atrophy genes even in the presence of normal calcineurin activity, and (iii) muscle‑specific overexpression of a dephosphorylation‑mimetic NFATc4 mutant will rescue HDAC3 binding and suppress atrophy despite low calcineurin levels.

Testable Predictions

1. ChIP‑qPCR for HDAC3 – Compare HDAC3 enrichment at the atrogin‑1 and MuRF1 enhancers in soleus from 3‑month vs 24‑month mice, and after 2 h denervation. Expect a significant age‑ and denervation‑dependent loss of HDAC3 binding [2][4].
2. HDAC3 inhibition – Treat young mice with the selective HDAC3 inhibitor RGFP966 for 48 h; measure atrogin‑1/MuRF1 mRNA and protein levels. Prediction: inhibition will increase atrophy‑gene expression to levels seen in old muscle, without altering calcineurin activity [5].
3. NFATc4‑DD mutant rescue – Generate a transgenic mouse expressing a NFATc4 mutant constitutively mimicking the dephosphorylated state (NFATc4‑DD). Cross into aged mice; assess muscle fiber CSA and atrogene expression. Prediction: NFATc4‑DD will maintain HDAC3 binding, attenuate atrogene up‑regulation, and preserve mass despite low calcineurin activity.
4. Atrogin‑1‑mediated calcineurin degradation – Use atrogin‑1‑KO mice subjected to denervation; evaluate calcineurin protein levels over time. Prediction: absence of atrogin‑1 will blunt calcineurin loss, breaking the feed‑forward loop and slowing atrophy [3].

Mechanistic Rationale

The hypothesis integrates three observations from the literature: (i) NFATc4’s constitutive nuclear localization suggests a repression role independent of neural activity [1]; (ii) NFAT proteins recruit HDACs to silencers [4]; (iii) atrogin‑1 directly targets calcineurin for degradation [3]. Age‑related calcineurin decline, already implicated in diabetes‑associated atrophy [5], would thus destabilize the NFATc4‑HDAC3 repressive complex, permitting basal expression of atrophy ligases. The ensuing atrogin‑1 surge accelerates calcineurin depletion, establishing a vicious cycle that links neuronal inactivity to molecular sarcopenia. This provides a testable, isoform‑specific mechanism that resolves the controversy over calcineurin’s dual role in hypertrophy versus atrophy: its activity is protective when it sustains NFATc4‑mediated repression, but detrimental when lost, allowing the atrophy program to proceed unchecked.